Summarized by Masters of Longevity from Longevity Technology.
Report on a patient-derived iPSC workflow for producing dopaminergic neuron precursors and its preclinical quality controls supporting clinical advancement.
Key Takeaways
- Aspen published preclinical data in Cell Stem Cell describing reproducible manufacturing of autologous iPSC-derived dopaminergic neuron precursor cells.
- The company combined whole-genome sequencing and an RNA-seq machine learning assay called NeuriTest for product genomic and transcriptomic quality control.
- Aspen reported improved motor function in preclinical models and no treatment-related findings in a nine-month GLP rodent safety study.
